Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Publication Information:
      BMC, 2020.
    • Publication Date:
      2020
    • Collection:
      LCC:Immunologic diseases. Allergy
    • Abstract:
      Abstract Background Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease (IBD) with unknown etiology. The lack of specific clinical manifestations, standard diagnostic criteria, objective and accurate indicators to the severity of the disease and the efficacy of the treatment, often results in difficulties in diagnosis and timely treatment of UC. Therefore, there is a need to develop a clinically suitable serum biomarker assay with high specificity and sensitivity. Objective and methods To explore the significance of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-saccharomyces cerevisiae antibodies (ASCA) in the diagnosis, differential diagnosis and treatment assessment in patients with ulcerative colitis (UC). Serum levels of ANCA-IgG, ASCA-IgA and ASCA-IgG were measured by an enzyme-linked immunosorbent assay (ELISA) in 105 UC patients, 52 non-UC patients and 100 healthy controls. Results (1) Both the ANCA-IgG level and its positive rate in UC patients were significantly higher than those in non-UC controls and healthy controls (p 0.05). (2) The sensitivity of ANCA+ and ANCA+/ASCA− in detecting UC patients was 61.90% and 55.24%, respectively, whereas the specificity was 91.45% and 94.08%, respectively. The sensitivity of ASCA+ and ASCA+/ANCA− in non-UC disease controls was 5.33% and 3.85%, respectively, and specificity was 83.9% and 88.78%, respectively. (3) When UC patients were grouped into mild, moderate or severe subtypes, the ANCA-IgG levels were correlated with the severity of UC, and the differences of the ANCA-IgG levels were statistically different among the three subtypes (p
    • File Description:
      electronic resource
    • ISSN:
      1710-1492
    • Relation:
      http://link.springer.com/article/10.1186/s13223-020-00433-1; https://doaj.org/toc/1710-1492
    • Accession Number:
      10.1186/s13223-020-00433-1
    • Rights:
      Journal Licence: CC BY
    • Accession Number:
      edsdoj.749b1ec88b3b455d826eabc8eb0a6a0a
  • Citations
    • ABNT:
      YANHUA PANG et al. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy, Asthma & Clinical Immunology, [s. l.], v. 16, n. 1, p. 1–5, 2020. DOI 10.1186/s13223-020-00433-1. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsdoj&AN=edsdoj.749b1ec88b3b455d826eabc8eb0a6a0a&custid=s8280428. Acesso em: 11 jul. 2020.
    • AMA:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun, Cuiping Xu. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy, Asthma & Clinical Immunology. 2020;16(1):1-5. doi:10.1186/s13223-020-00433-1.
    • AMA11:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun, Cuiping Xu. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy, Asthma & Clinical Immunology. 2020;16(1):1-5. doi:10.1186/s13223-020-00433-1
    • APA:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun, & Cuiping Xu. (2020). Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy, Asthma & Clinical Immunology, 16(1), 1–5. https://doi.org/10.1186/s13223-020-00433-1
    • Chicago/Turabian: Author-Date:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun, and Cuiping Xu. 2020. “Assessment of Clinical Activity and Severity Using Serum ANCA and ASCA Antibodies in Patients with Ulcerative Colitis.” Allergy, Asthma & Clinical Immunology 16 (1): 1–5. doi:10.1186/s13223-020-00433-1.
    • Harvard:
      Yanhua Pang et al. (2020) ‘Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis’, Allergy, Asthma & Clinical Immunology, 16(1), pp. 1–5. doi: 10.1186/s13223-020-00433-1.
    • Harvard: Australian:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun & Cuiping Xu 2020, ‘Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis’, Allergy, Asthma & Clinical Immunology, vol. 16, no. 1, pp. 1–5, viewed 11 July 2020, .
    • MLA:
      Yanhua Pang, et al. “Assessment of Clinical Activity and Severity Using Serum ANCA and ASCA Antibodies in Patients with Ulcerative Colitis.” Allergy, Asthma & Clinical Immunology, vol. 16, no. 1, May 2020, pp. 1–5. EBSCOhost, doi:10.1186/s13223-020-00433-1.
    • Chicago/Turabian: Humanities:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun, and Cuiping Xu. “Assessment of Clinical Activity and Severity Using Serum ANCA and ASCA Antibodies in Patients with Ulcerative Colitis.” Allergy, Asthma & Clinical Immunology 16, no. 1 (May 1, 2020): 1–5. doi:10.1186/s13223-020-00433-1.
    • Vancouver/ICMJE:
      Yanhua Pang, Huijie Ruan, Dongfang Wu, Yanfei Lang, Ke Sun, Cuiping Xu. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy, Asthma & Clinical Immunology [Internet]. 2020 May 1 [cited 2020 Jul 11];16(1):1–5. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsdoj&AN=edsdoj.749b1ec88b3b455d826eabc8eb0a6a0a&custid=s8280428